​

Funding Round

Series C - Jinfang Pharmaceutical

Series C - Jinfang Pharmaceutical

Investment Firm

Overview

Jinfang Pharmaceutical is focused on R&D and drug development from small molecule drug pipelines to diversified cutting-edge therapies.

Announced Date

Mar 09, 2023

Funding Type

Series C

Highlights

N/A

Location

Asia

Social

N/A

Investor Lead

Huagai Capital

Huagai Capital

Huagai Capital is a early_stage_venture and late_stage_venture and private_equity firm.

Participant Investors

6

Investor Name
Participant InvestorShanjin Capital
Participant InvestorHuimei Capital
Participant InvestorPan-Lin Capital
Participant InvestorHuagai Capital
Participant InvestorCDH Investments

Round Details and Background

Jinfang Pharmaceutical raised $70353779 on 2023-03-09 in Series C

Jinfang Pharmaceutical is focused on R&D and drug development from small molecule drug pipelines to diversified cutting-edge therapies.

Company Funding History

3

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Mar 09, 2023
Series C - Jinfang Pharmaceutical
12-70.4M
Aug 29, 2023
Venture Round - Jinfang Pharmaceutical
2-undefined
Aug 03, 2020
Series B - Jinfang Pharmaceutical
7-57.3M

Recent Activity

There is no recent news or activity for this profile.